Zongertinib
As of the edition of 20 October 2026, Zongertinib is a small molecule: marketed, first approved in 2025 (US); acts on ERBB2; US protection ends in 2041.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Hernexeos
- First approved
- 8 August 2025 (US)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Nippon Boehringer Ingelheim Co., Ltd.; 2 holders in all
- Registered trials
- 18, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue
US protection
US protection ends in 2041.
The last listed US drug-substance patent ends in 2041. The application that gives this date is held by Boehringer Ingelheim.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Zongertinib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | P04626 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 12 | 10 | 2 | 0 |
| Phase 2 | 4 | 0 | 4 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 18 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Originator and Lead sponsor of trials | 2021 to now |